Question 1

What is Beam Therapeutics Inc. Common Stock's WACC?

Accepted Answer

Beam Therapeutics Inc. Common Stock (BEAM) has a Weighted Average Cost of Capital (WACC) of 11.36%. This is calculated using a Cost of Equity of 11.68% (via CAPM with a beta of 2.02) and a pre-tax Cost of Debt of 2.00%, with an equity weight of 96.68% in the capital structure.

Question 2

Is Beam Therapeutics Inc. Common Stock's WACC high or low?

Accepted Answer

Beam Therapeutics Inc. Common Stock's WACC of 11.36% falls within the typical 8-12% range for mid-cap growth companies. WACC is used as the discount rate in DCF valuations — a lower WACC results in higher present values of future cash flows.

Question 3

How is Beam Therapeutics Inc. Common Stock's WACC calculated?

Accepted Answer

Beam Therapeutics Inc. Common Stock's WACC is calculated using the formula: WACC = (E/V × Re) + (D/V × Rd × (1-T)). The Cost of Equity (Re) of 11.68% is derived from the CAPM model using a beta of 2.02. The pre-tax Cost of Debt (Rd) is 2.00%. The capital structure is 96.68% equity and 3.32% debt.

Beam Therapeutics Inc. Common Stock (BEAM) — WACC 分析

WACC 构成

解读

Beam Therapeutics Inc. Common Stock（BEAM）WACC：11.36%

WACC计算器

Beam Therapeutics Inc. Common Stock（BEAM） WACC 解读

BEAM 公司分析

BEAM DCF 估值

继续做同行对比